ABBV vs SLB: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
SLB N.V. · Energy
$51.92
-20.2% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
SLB |
| Current Price |
$208.05 |
$51.92 |
| Fair Value Estimate |
$217.50 |
$41.43 |
| Upside to Fair Value |
+4.5%
|
-20.2%
|
| Market Cap |
$367.9B |
$77.9B |
| Forward P/E |
14.9x
|
18.6x
|
| EV / EBITDA |
16.7x
|
9.2x
|
| Price / Sales |
6.1x
|
2.2x
|
| Price / FCF |
20.9x
|
16.1x
|
| Revenue Growth YoY |
+8.6%
|
-1.6%
|
| Gross Margin |
83.7%
|
18.21%
|
| Operating Margin |
34.7%
|
15.28%
|
| Return on Equity |
-129.24%
|
12.83%
|
| Dividend Yield |
3.2% |
2.21% |
| FCF Yield |
4.78%
|
6.21%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
SLB is the world's largest oilfield services company with $35.7B in FY2025 revenue, operating across four divisions: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems. The company completed the ChampionX acquisition in 2025 and is pursuing a digital transformation and AI-driven strategy. At $51.92, SLB trades at 2.18x P/S (in the fair range of the 5-year di…
Accumulation Zones
| Metric |
ABBV |
SLB |
| Zone Low |
$163.13 |
$34.00 |
| Zone High |
$184.88 |
$39.00 |
| In Buy Zone? |
No
|
No
|